RT Journal Article
SR Electronic
T1 Replacement of the Gamma by the Delta variant in Brazil: impact of lineage displacement on the ongoing pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.27.21268309
DO 10.1101/2021.12.27.21268309
A1 Giovanetti, Marta
A1 Fonseca, Vagner
A1 Wilkinson, Eduan
A1 Tegally, Houriiyah
A1 San, Emmanuel James
A1 Althaus, Christian L.
A1 Xavier, Joilson
A1 Slavov, Svetoslav Nanev
A1 Viala, Vincent Louis
A1 Ranieri Jerônimo Lima, Alex
A1 Ribeiro, Gabriela
A1 Souza-Neto, Jayme A.
A1 Fukumasu, Heidge
A1 Coutinho, Luiz Lehmann
A1 Venancio da Cunha, Rivaldo
A1 Freitas, Carla
A1 Campelo de A e Melo, Carlos F
A1 Navegantes, Wildo
A1 do Carmo Said, Rodrigo Fabiano
A1 Almiron, Maria
A1 de Oliveira, Tulio
A1 Sampaio, Sandra Coccuzzo
A1 Elias, Maria Carolina
A1 Covas, Dimas Tadeu
A1 Holmes, Edward C.
A1 Lourenço, Jose
A1 Kashima, Simone
A1 de Alcantara, Luiz Carlos Junior
YR 2021
UL http://medrxiv.org/content/early/2021/12/29/2021.12.27.21268309.abstract
AB The COVID-19 epidemic in Brazil was driven mainly by the spread of Gamma (P.1), a locally emerged Variant of Concern (VOC) that was first detected in early January 2021. This variant was estimated to be responsible for more than 96% of cases reported between January and June 2021, being associated with increased transmissibility and disease severity, a reduction in neutralization antibodies and effectiveness of treatments or vaccines, as well as diagnostic detection failure. Here we show that, following several importations predominantly from the USA, the Delta variant rapidly replaced Gamma after July 2021. However, in contrast to what was seen in other countries, the rapid spread of Delta did not lead to a large increase in the number of cases and deaths reported in Brazil. We suggest that this was likely due to the relatively successful early vaccination campaign coupled with natural immunity acquired following prior infection with Gamma. Our data reinforces reports of the increased transmissibility of the Delta variant and, considering the increasing concern due to the recently identified Omicron variant, argues for the necessity to strengthen genomic monitoring on a national level to quickly detect and curb the emergence and spread of other VOCs that might threaten global health.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part through National Institutes of Health USA grant U01 AI151698 for the United World Arbovirus Research Network (UWARN), the CRP ICGEB RESEARCH GRANT 2020 Project CRP/BRA20-03, Contract CRP/20/03, the Oswaldo Cruz Foundation VPGDI-027-FIO-20-2-2-30, the Brazilian Ministry of Health (SCON2021-00180), the CNPq (426559/2018-5) and the Faperj E-26/202.930/2016. MG and LCJA are supported by Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) (E-26/202.248/2018(238504); E26/202.665/2019(247400)). CA received funding from the European Union s Horizon 2020 research and innovation programme, project EpiPose (No 101003688). Research reported in this publication/article was also supported by the South African Department of Science and Innovation (DSI) and the South African Medical Research Council (SAMRC) under the BRICS JAF #2020/049. The content and findings reported/illustrated herein are the sole deduction, view and responsibility of the researcher/s and do not reflect the official position and sentiments of the funders.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved by the Ethics Review Committee of the Pan American Health Organization (PAHOERC.0344.01) and by the Federal University of Minas Gerais (CEP/CAAE: 32912820.6.1001.5149). The availability of these samples for research purposes during outbreaks of national concern is allowed under the terms of the 510/2016 Resolution of the National Ethical Committee for Research, Brazilian Ministry of Health (CONEP - Comissao Nacional de Etica em Pesquisa, Ministerio da Saude) that authorize, without the necessity of an informed consent, the use of clinical samples collected in the Brazilian Central Public Health Laboratories to accelerate knowledge building and contribute to surveillance and outbreak response. The samples processed in this study were obtained anonymously from material exceeding the routine diagnosis in Brazilian public health laboratories that belong to the public network within BrMoH.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll SARS-CoV-2 whole genome sequences produced by the National Network for Pandemic Alert of SARS-CoV-2 have been deposited in the GISAID sequence database and are publicly available subject to the terms and conditions of the GISAID database. The GISAID accession numbers of sequences used in the phylogenetic analysis, are provided in the Supplementary Table S1. https://www.gisaid.org/ https://www.gisaid.org/